Immucell announces submission of CMC Technical Section to FDA

ImmuCell Corporation announced that it recently submitted the Chemistry, Manufacturing and Controls, CMC, Technical Section for Re-Tain to the FDA. On August 10, 2023, the Company issued a disclosure stating that it anticipated making this submission “shortly” after the filing of its Quarterly Report on Form 10-Q. The Company is now confirming that this objective was achieved. “For the benefit of clarity, we want to inform investors that this important step in the regulatory process was taken on August 18, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell. “This kind of submission is subject to a six-month review by the FDA, and we are excited about the opportunity ahead.”